Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the ...
| Ticker |
Sentiment |
Impact |
|
ASND
|
Neutral
|
10 %
|
|
RPRX
|
Somewhat Bullish
|
28 %
|
|
ABBV
|
Neutral
|
3 %
|
